Skip to main content
Equibles

ADVENZYMES · Advanced Enzyme Technologies Limited · Documents

Use ADVENZYMES with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADVENZYMES.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
283.10 INR -0.80 (-0.28%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 2813 Avg daily vol (3M) 10.27K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 3, 2026
2026
Nov 3
Earnings call
Q2 FY27 revenue rises 16%, EBITDA 20%, PAT 14%

Advanced Enzyme Technologies Limited reported Q2 FY27 revenue of INR2,145 million, up 16% year-on-year, EBITDA of INR721 million, up 20%, and PAT of INR512 million, up 14%; management targets 30% to 32% EBITDA margins.

5 source passages
Advanced Enzyme Technologies Limited Q2 and H1 FY27 Earnings Conference Call. Our top line for the quarter stood at INR2,145 million, registering a growth of 16% year-on-year and 12% on a sequential basis, while the first half of financial year '27 revenue grew by 10% over the corresponding period last year. EBITDA increased to INR721 crores, up 20% year-on-year and 36% sequentially, while the same grew by 7% on a year-to-date basis. Profit after tax, PAT, stood at INR512 million, grew by 14% year-onyear basis, 33% sequential basis and 5% on a YTD basis. So we are saying that as of now, for calculation purpose, we are going with 30% to 32% of EBITDA level. Open the document at this passage
Showing 1–2 of 2 documents